Abstract:Objective:The aims of this study were to present evidence to develop and validate the Japanese Tumor-Node-Metastasis (TNM) staging system for primary liver cancer and to compare its discriminatory ability and predictive power with those of Vauthey's simplified staging, which was adopted as the TNM staging system of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC). Summary Background Data:Among many staging systems for hepatocellular carcinoma, the Japanese TNM staging system and the AJCC/UICC staging system were developed based on a survival analysis of surgical patients. These 2 staging systems have not been compared in large series. Methods:The Liver Cancer Study Group of Japan (LCSGJ) prospectively collected clinicopathologic data of 63,736 patients with primary liver cancer from 1995 to 2001. Among them, 13,772 patients received curative hepatic resection. Based on univariate and multivariate survival analyses, the Japanese TNM staging system was developed. The accuracy of the Japanese TNM staging system for predicting patient survival was compared with that of the AJCC/UICC staging system using the cross-validation method. Results:The independent prognostic factors (relative risk; 95% confidence interval) were vascular or bile duct invasion (1.36;1.29–1.43), liver cirrhosis (1.26;1.20–1.32), diameter (≤2 cm or >2 cm) (1.21;1.14–1.28), alpha-fetoprotein (1.20;1.15–1.25), single/multiple (1.18;1.12–1.23), liver damage (1.15;1.10–1.20), hepatic involvement (1.14;1.09–1.19), histologic differentiation (1.14;1.08–1.20), gross classification (1.13;1.08–1.18), and esophageal varices (1.07;1.02–1.13). Based on these results, 3 criteria (vascular or bile duct invasion, diameter, and single/multiple) were selected. Patients with none of these 3 factors were considered T1, and those with 1, 2, and 3 factors were T2, T3, and T4, respectively. The number of patients and 5-year survival rates for T1, T2, T3, and T4 were 2078, 70%; 6853, 58%; 3021, 41%; and 582, 24% (P < 0.0001), respectively, while those for the AJCC-T were 8457, 61% in T1, 2888, 46% in T2, and 1189, 30% in T3 (P < 0.0001). While both the LCSGJ-T and the AJCC-T had good discriminating ability, the former was significantly superior (P = 0.0007). Conclusions:Our findings support the development of LCSG stage. While both staging systems allow for the clear stratification of patients into prognostic groups, the LCSGJ staging may be more appropriate for stratifying patients with early-stage HCC.

Staging of Hepatocellular Carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan

The Chinese Classification System Compared with TNM Staging in Prognosis of Patients with Primary Hepatic Carcinoma after Resection.

LCSGJ-T Classification, 6th or 5th Edition TNM Staging Did Not Independently Predict the Long-Term Prognosis of HBV-related Hepatocellular Carcinoma after Radical Hepatectomy.

A comparison of three different staging systems of hilar cholangiocarcinoma

Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma

[Comparison of the Predictive Values of Eight Staging Systems for Primary Liver Cancer in Prognosis of Combined Hepatocellular-cholangiocellular Carcinoma Patients after Surgery]

Comparison of Different Clinical Staging Systems for Hepatocellular Carcinoma

Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

A Modified Jarnagin-Blumgart Classification Better Predicts Survival for Resectable Hilar Cholangiocarcinoma

Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: A retrospective cohort study: A Staging System for Hepatoid Adenocarcinoma of the Stomach

Both the 5th and 6th Editions of TNM Staging System Fail to Independently Predict Long-term Prognosis after Radical Hepatectomy in Hepatocellular Carcinoma Sized > or = 5 Cm

Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis

Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy

Comparison of Four Staging Systems in Predicting Outcomes and Guiding Option of Treatment for Patients with Hepatocellular Carcinoma

Prognostic Accuracy of Staging Systems in Patients with Primary Liver Cancer Undergoing Transarterial Chemoembolization.

Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress

Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma

A Comparison the 7th and 8th Edition AJCCTNM Staging Systems for Predicting Disease Free Survival Time after Surgery in Primary Liver Cancer Patients

Prognostic Accuracy of Staging Systems in Patients with Primary Liver Cancer Treated with Transarterial Chemoembolization